研究单位:[1]Innostellar Biotherapeutics Co.,Ltd[2]Beijing Tongren Hospital, Capital Medical University,Beijing,China[3]Shanghai General Hospital,Shanghai,China
研究目的:
The purpose of the study is to evaluate the safety, tolerability and efficacy of LX101 in subjects with biallelic RPE65 mutation-associated inherited retinal dystrophy.